Compare AMLX & AXGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMLX | AXGN |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 2021 | 2013 |
| Metric | AMLX | AXGN |
|---|---|---|
| Price | $14.55 | $42.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | $21.56 | ★ $42.33 |
| AVG Volume (30 Days) | 948.4K | ★ 1.0M |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.46 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $380,786,000.00 | $225,208,000.00 |
| Revenue This Year | N/A | $20.57 |
| Revenue Next Year | N/A | $16.68 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 1612.94 | 20.21 |
| 52 Week Low | $4.64 | $9.22 |
| 52 Week High | $18.61 | $45.83 |
| Indicator | AMLX | AXGN |
|---|---|---|
| Relative Strength Index (RSI) | 36.65 | 63.58 |
| Support Level | $13.02 | $29.48 |
| Resistance Level | $15.37 | $45.83 |
| Average True Range (ATR) | 0.86 | 1.92 |
| MACD | -0.32 | 0.18 |
| Stochastic Oscillator | 0.00 | 64.24 |
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.